Posted by Michael Wonder on 23 Jul 2020
Spravato (esketamine) nasal spray is available for Canadian patients
22 July 2020 - A new anti-depressant with a novel mechanism of action to treat major depressive disorder in adults.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Spravato (esketamine), following a notice of compliance from Health Canada, is now available for Canadian patients.
Spravato nasal spray, the first glutamate receptor modulator approved for the treatment of major depressive disorder (MDD), is indicated for use in combination with an oral anti-depressant (that is either a SSRI or SNRI) for the treatment of MDD in adults who have not responded adequately to at least two separate courses of treatment with different anti-depressants, each of adequate dose and duration, in the current moderate to severe depressive episode.
